Open Access

A four‑gene signature for prognosis in breast cancer patients with hypermethylated IL15RA

  • Authors:
    • Hui Yang
    • Li Zhou
    • Jianhua Chen
    • Jiang Su
    • Wei Shen
    • Biao Liu
    • Jundong Zhou
    • Shiyou Yu
    • Jun Qian
  • View Affiliations

  • Published online on: March 12, 2019     https://doi.org/10.3892/ol.2019.10137
  • Pages: 4245-4254
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have revealed that upregulation of interleukin 15 receptor α (IL15RA) contributes to improved prognosis of breast cancer. The present study aimed to elucidate the molecular mechanisms underlying the antitumor effect induced by IL15RA upregulation, and to identify a gene signature capable of predicting the survival of patients with breast cancer. Using paired gene expression and methylation data of breast cancer samples from The Cancer Genome Atlas data portal, differentially expressed genes (DEGs) were identified in hypermethylated and hypomethylated IL15RA breast cancer samples. Furthermore, a gene signature‑based risk‑scoring model was developed according to the Cox regression coefficients of survival‑associated DEGS. The gene signature was applied to classify patients with breast cancer and hypermethylated IL15RA into two risk groups via Kaplan‑Meier survival analysis of overall survival (OS) time. Functional enrichment analysis was conducted to decipher the biological roles of the DEGs between the two risk groups. A total of 326 DEGs were present in the hypomethylation and hypermethylation samples compared with in the normal samples. A four‑gene signature [SH3 and cysteine rich domain 2 (STAC2), proline rich 11 (PRR11), homeobox C11 (HOXC11) and nucleolar and spindle associated protein 1 (NUSAP1)] was identified as able to successfully separate patients with breast cancer and hypermethylated IL15RA into two risk groups with significantly different OS time. The signature revealed similar predictive performance in an independent set. Significant enrichment of the ‘receptor interaction’ and ‘cell adhesion molecules (CAM)’ pathways, which involved the DEGs, occurred between the two risk groups. These findings suggested that IL15RA may participate in the regulation of STAC2, PRR11, HOXC11, NUSAP1, and ‘ECM‑receptor interaction’ and ‘cell adhesion molecules’ pathways, and therefore in the suppression of breast cancer development and progression. The four‑gene signature may have potential prognostic value for breast cancer.
View Figures
View References

Related Articles

Journal Cover

May 2019
Volume 17 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Yang, H., Zhou, L., Chen, J., Su, J., Shen, W., Liu, B. ... Qian, J. (2019). A four‑gene signature for prognosis in breast cancer patients with hypermethylated IL15RA. Oncology Letters, 17, 4245-4254. https://doi.org/10.3892/ol.2019.10137
MLA
Yang, H., Zhou, L., Chen, J., Su, J., Shen, W., Liu, B., Zhou, J., Yu, S., Qian, J."A four‑gene signature for prognosis in breast cancer patients with hypermethylated IL15RA". Oncology Letters 17.5 (2019): 4245-4254.
Chicago
Yang, H., Zhou, L., Chen, J., Su, J., Shen, W., Liu, B., Zhou, J., Yu, S., Qian, J."A four‑gene signature for prognosis in breast cancer patients with hypermethylated IL15RA". Oncology Letters 17, no. 5 (2019): 4245-4254. https://doi.org/10.3892/ol.2019.10137